FDA Modernization Act 2.0: transitioning beyond animal models with human cells, organoids, and AI/ML-based approaches
Journal of Clinical Investigation · 01.11.2023 · 133 (21)
DOI: 10.1172/jci175824 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 01.11.2023. Verfasst von Peter-James H Zushin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Stanford Cardiovascular Institute and. Hauptthemen laut MEDLINE: Drug Approval, Organoids. Die Arbeit wurde bisher 370-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIBIB NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Stanford Cardiovascular Institute and.
- Department of Medicine (Division of Cardiology), Stanford University, Stanford, California, USA.
- Greenstone Biosciences, Palo Alto, California, USA.
Förderung
- NIBIB NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Zushin, P. H., Mukherjee, S., & Wu, J. C. (2023). FDA Modernization Act 2.0: transitioning beyond animal models with human cells, organoids, and AI/ML-based approaches. Journal of Clinical Investigation, 133(21). https://doi.org/10.1172/jci175824
Vancouver
Zushin PH, Mukherjee S, Wu JC. FDA Modernization Act 2.0: transitioning beyond animal models with human cells, organoids, and AI/ML-based approaches. Journal of Clinical Investigation. 2023;133(21). doi:10.1172/jci175824
BibTeX
@article{Zushin2023,
author = {Zushin, Peter-James H and Mukherjee, Souhrid and Wu, Joseph C},
title = {FDA Modernization Act 2.0: transitioning beyond animal models with human cells, organoids, and AI/ML-based approaches},
journal = {Journal of Clinical Investigation},
year = {2023},
volume = {133},
number = {21},
doi = {10.1172/jci175824}
}
EUVIMED